Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Date:6/27/2008

nt in everyday functioning," said Janet Vergis, President of McNeil Pediatrics(TM). "Recognizing this need -- and as the market leader in extended-release MPH for children and adolescents -- we see today's approval as a treatment option milestone for adults with ADHD and their healthcare professionals. We are proud to offer patients ages 6 to 65 with ADHD our CONCERTA(R) product knowledge based on more than seven years of clinical experience."

Researchers examining ADHD across the lifespan have noted the condition is often chronic, with prominent symptoms and impairment spanning into adulthood, and is often associated with co-occurring anxiety, mood and disruptive disorders as well as substance abuse(3). According to the NIMH, ADHD is thought to be a biological condition, usually inherited, and tends to run in some families more than others. Often when a child is diagnosed with the disorder, a parent will recognize that he or she had many of the same symptoms, and for the first time, will begin to understand some of the traits that have troubled them for years(4). All aspects of an individual's life must be considered in the diagnosis and treatment of ADHD(3).

Today's FDA approval was based on clinical trial data in adults ages 18 to 65. In these studies, use of CONCERTA(R) was shown to significantly improve ADHD symptoms such as attention, impulsivity and hyperactivity compared to placebo, and the medication was shown to be generally well tolerated.

About CONCERTA(R)

CONCERTA(R) is approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

IMPORTANT SAFETY INFORMATION

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

CONCERTA(R) should not be taken by patients who have: allergies to methylph
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader ... Iowa State University won first place in the ... HC-2ex, the team’s solution achieved the highest overall performance ... second place finisher. , Experts from all segments of ... long challenge, using a variety of design tools, hardware ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, ... Geography Trend and Forecast (2011 - 2016)," analyzes ... and studies the major market drivers, restraints, and opportunities ... Asia. , The global chocolate market is expected to ... 2016 at an estimated CAGR of 2.7% from 2011 ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... New DNA-Based Test Produces Decisive Result Within ... Enigma Diagnostics,the life sciences company developing ... it has successfully completed a project,commissioned by ... to,develop a rapid, point-of-care diagnostic system for ...
... Agreement in Principle with U.S. Attorney,s Office; ... Earnings Exceed Company Guidance;,Company Again ... Pa., Nov. 8 Cephalon, Inc. (Nasdaq:,CEPH) today reported third ... $457.2 million for the third quarter of 2006 and,within the ...
... ExonHit Therapeutics, a,drug and diagnostic discovery company, has ... test. The company expects to have,this test certified ... its GLP (Good,Laboratory Practices) compliant laboratories to the ... ExonHit test aims to identify patients suffering from,Alzheimer,s ...
Cached Biology Technology:Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 2Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 3Cephalon Announces Strong Third Quarter Financial Results 2Cephalon Announces Strong Third Quarter Financial Results 3Cephalon Announces Strong Third Quarter Financial Results 4Cephalon Announces Strong Third Quarter Financial Results 5Cephalon Announces Strong Third Quarter Financial Results 6Cephalon Announces Strong Third Quarter Financial Results 7Cephalon Announces Strong Third Quarter Financial Results 8Cephalon Announces Strong Third Quarter Financial Results 9Cephalon Announces Strong Third Quarter Financial Results 10Cephalon Announces Strong Third Quarter Financial Results 11Cephalon Announces Strong Third Quarter Financial Results 12Cephalon Announces Strong Third Quarter Financial Results 13Cephalon Announces Strong Third Quarter Financial Results 14Cephalon Announces Strong Third Quarter Financial Results 15Cephalon Announces Strong Third Quarter Financial Results 16Cephalon Announces Strong Third Quarter Financial Results 17Cephalon Announces Strong Third Quarter Financial Results 18ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 2ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 3ExonHit Completes a Prototype to Detect Alzheimer's Disease From Blood 4
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/16/2014)... Conn. , October 16, 2014 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... its leading edge technologies including Wocket™, the Smart Wallet, ... (FiRe) Conferenece. FiRe is a leading global conference on ... Hosted by Mark Anderson , founder and ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Sanctuary have collected the first camera trap video footage ... individuals remaining, Cross River gorillas are the world,s rarest ... by field researchers. Collected from one of four ... protected area, the footage reveals eight Cross River gorillas ...
... CUNY Energy Institute, which has been developing innovative low-cost ... discharge rates and high energy densities, announced that it ... The Institute said large-scale commercialization of the battery would ... an environmentally friendlier and less costly alternative to nickel ...
... to develop more efficient biofuel cells, seen as the future ... biological materials, they have the potential to be used indefinitely ... possible to replace a battery or recharge them. , Most ... the Leeds research will focus on bacterial enzymes that can ...
Cached Biology News:Camera trap video offers rare glimpse of world's rarest gorilla 2CUNY Energy Institute battery system could reduce buildings' electric bills 2Creating energy from light and air - new research on biofuel cells 2
Cytofix Buffer 100 mls...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Perm/Wash Buffer 250 Tests...
PCR purification kit, 100 preps...
Biology Products: